Filtered By:
Condition: Thrombosis
Countries: Japan Health
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 297 results found since Jan 2013.
Development of Biomembrane-mimetic Nanoparticles for the Treatment of Ischemic Stroke
Yakugaku Zasshi. 2021;141(9):1071-1078. doi: 10.1248/yakushi.21-00114.ABSTRACTIncrease in vascular permeability of the blood-brain barrier (BBB) is a distinct pathology following ischemic stroke. In previous studies, we demonstrated that liposomal drug delivery system (DDS)-based delivery of neuroprotectants is useful for treating cerebral ischemia/reperfusion injury. Additionally, our previous studies reported that combination therapy with liposomal fasudil plus tissue plasminogen activator (t-PA), a thrombolytic agent, brings about decrease in the risk of t-PA-derived cerebral hemorrhage and prolong the therapeutic time ...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - September 2, 2021 Category: Drugs & Pharmacology Authors: Tatsuya Fukuta Source Type: research
Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech)
AbstractReports of cerebral venous sinus thrombosis and intracranial hemorrhage (ICH) following the administration of coronavirus vaccines have raised concerns regarding their safety. Although no regulatory authority has recognized ICH as an adverse event associated with tozinameran (BNT162b2, Pfizer-BioNTech), fatal and non-fatal cases have been reported. In Japan, 10 fatal cases (five men and women) have been reported to date. Four of the five women died of ICH and the other died of aspiration pneumonia, whereas all five men died of causes other than stroke. This imbalance is incompatible with the mortality data on cardi...
Source: Journal of Pharmaceutical Policy and Practice - May 31, 2021 Category: Pharmaceuticals Source Type: research
Clinical Experience of Percutaneous Patent Foramen Ovale Closure using the Amplatzer PFO Occluder in Japanese Patients to Prevent the Recurrence of Cryptogenic Stroke
Conclusion: Percutaneous closure using Amplatzer PFO occluder is a safe procedure for Japanese patients However, further investigations with a larger sample and longer follow-up are needed to confirm this result.PMID:34024855 | DOI:10.2169/internalmedicine.7188-21
Source: Internal Medicine - May 24, 2021 Category: Internal Medicine Authors: Hiroya Takafuji Kotaro Obunai Yu Makihara Nahoko Kato Hiroyuki Watanabe Source Type: research
Ischemic/bleeding event after short dual-antiplatelet therapy in patients with high bleeding risk: Sub-analysis of the MODEL U-SES study
CONCLUSION: In contemporary PCI practice, nearly half of patients had HBR and presence of HBR significantly increased risk of ischemic/thrombotic events. Both aspirin and P2Y12 inhibitor monotherapy following short DAPT had low and comparable ischemic/bleeding events.PMID:33875313 | DOI:10.1016/j.jjcc.2021.03.015
Source: Journal of Cardiology - April 20, 2021 Category: Cardiology Authors: Hirofumi Hioki Ken Kozuma Yoshihisa Kinoshita Mamoru Nanasato Yoshiaki Ito Junichi Yamaguchi Nobuo Shiode Kiyoshi Hibi Kengo Tanabe Junya Ako Yoshihiro Morino Atsushi Hirohata Shinjo Sonoda Yoshihisa Nakagawa Hisayuki Okada Takuo Nakagami Itaru Takamisawa Source Type: research
Leukocyte Count and Risks of Stroke and Coronary Heart Disease: The Circulatory Risk in Communities Study (CIRCS)
CONCLUSION: Leukocyte count was positively associated with the risks of ischemic stroke and coronary heart disease among the general Japanese population, especially in current smokers.PMID:33746157 | DOI:10.5551/jat.60889
Source: Journal of Atherosclerosis and Thrombosis - March 22, 2021 Category: Cardiology Authors: Jiaqi Li Hironori Imano Kazumasa Yamagishi Mari Tanaka Renzhe Cui Isao Muraki Mitsumasa Umesawa Mina Hayama-Terada Tetsuya Ohira Masahiko Kiyama Takeo Okada Tomoko Sankai Takeshi Tanigawa Akihiko Kitamura Hiroyasu Iso CIRCS Investigators Source Type: research
